Skip to content
Trilostane
Modrastane (trilostane) is a small molecule pharmaceutical. Trilostane was first approved as Modrastane on 1984-12-31. The pharmaceutical is active against 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trilostane
Tradename
Company
Number
Date
Products
MODRASTANEBioenvisionN-018719 DISCN1984-12-31
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02C: Antiadrenal preparations
— H02CA: Anticorticosteroids
— H02CA01: Trilostane
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3—1—15
DementiaD003704F03——1——1
Psychophysiologic disordersD011602F45.9——1——1
SchizophreniaD012559EFO_0000692F20——1——1
DepressionD003863F33.9——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnxietyD001007EFO_0005230F41.1—1——12
PainD010146EFO_0003843R52—1———1
Substance-related disordersD019966EFO_0003890F13—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dental anxietyD016854————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRILOSTANE
INNtrilostane
Description
Trilostane, sold under the brand names Modrenal and Vetoryl among others, is a medication which has been used in the treatment of Cushing's syndrome, Conn's syndrome, and postmenopausal breast cancer in humans. It was withdrawn for use in humans in the United States in the 1990s but was subsequently approved for use in veterinary medicine in the 2000s to treat Cushing's syndrome in dogs. It is taken by mouth.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C#N)C[C@]35C)[C@@H]1CC[C@@H]2O
Identifiers
PDB—
CAS-ID13647-35-3
RxCUI38668
ChEMBL IDCHEMBL1200907
ChEBI ID32260
PubChem CID656583
DrugBankDB01108
UNII IDL0FPV48Q5R (ChemIDplus, GSRS)
Target
Agency Approved
HSD3B2
HSD3B2
Organism
Homo sapiens
Gene name
HSD3B2
Gene synonyms
HSDB3B
NCBI Gene ID
3284
Protein name
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2
Protein synonyms
3 beta-HSD type II, 3 beta-hydroxysteroid dehydrogenase type II, delta 5-delta 4-isomerase type II, 3 beta-HSD type II, 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II, 3-beta-HSD adrenal and gonadal type, 3-beta-HSD II, 3-beta-hydroxy-5-ene steroid dehydrogenase, 3-beta-hydroxy-Delta(5)-steroid dehydrogenase, delta 5-delta 4-isomerase type II, progesterone reductase, short chain dehydrogenase/reductase family 11E, member 2
Uniprot ID
Q9UD08
Mouse ortholog
—
—
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 560 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,804 adverse events reported
View more details